These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 32349381)

  • 1. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
    Darcis G; Berkhout B; Pasternak AO
    Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
    Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
    Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential implication of residual viremia in patients on effective antiretroviral therapy.
    Sahu GK
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):25-35. PubMed ID: 25428885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
    Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
    Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.
    Reeves DB; Duke ER; Wagner TA; Palmer SE; Spivak AM; Schiffer JT
    Nat Commun; 2018 Nov; 9(1):4811. PubMed ID: 30446650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.
    Wang X; Xu H
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33670027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual inflammation and viral reservoirs: alliance against an HIV cure.
    Massanella M; Fromentin R; Chomont N
    Curr Opin HIV AIDS; 2016 Mar; 11(2):234-41. PubMed ID: 26575148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
    Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
    mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.
    Shen L; Siliciano RF
    J Allergy Clin Immunol; 2008 Jul; 122(1):22-8. PubMed ID: 18602567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. As good as it gets? The problem of HIV persistence despite antiretroviral drugs.
    Sigal A; Baltimore D
    Cell Host Microbe; 2012 Aug; 12(2):132-8. PubMed ID: 22901535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.
    Chun TW; Justement JS; Murray D; Hallahan CW; Maenza J; Collier AC; Sheth PM; Kaul R; Ostrowski M; Moir S; Kovacs C; Fauci AS
    AIDS; 2010 Nov; 24(18):2803-8. PubMed ID: 20962613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutics for HIV-1 reactivation from latency.
    Sgarbanti M; Battistini A
    Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Reservoirs During Suppressive Therapy.
    Barton K; Winckelmann A; Palmer S
    Trends Microbiol; 2016 May; 24(5):345-355. PubMed ID: 26875617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of viral reservoirs in HIV-1 infection.
    Blankson JN; Persaud D; Siliciano RF
    Annu Rev Med; 2002; 53():557-93. PubMed ID: 11818490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
    Chou TC; Maggirwar NS; Marsden MD
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Splice of Life: Does RNA Processing Have a Role in HIV-1 Persistence?
    Pasternak AO; Berkhout B
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
    Katlama C; Deeks SG; Autran B; Martinez-Picado J; van Lunzen J; Rouzioux C; Miller M; Vella S; Schmitz JE; Ahlers J; Richman DD; Sekaly RP
    Lancet; 2013 Jun; 381(9883):2109-17. PubMed ID: 23541541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.